Text Size
1482 studies found for:    "Neuroendocrine Tumors"

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Terminated A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors
Conditions: Neuroendocrine Tumors;   Carcinoid Tumors;   Adrenal Gland Tumors;   Neuroblastoma;   Pancreatic Neuroendocrine Tumors;   Multiple Endocrine Neoplasia
Interventions: Drug: pertuzumab;   Drug: erlotinib
2 Recruiting RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe
Conditions: Carcinoma;   Neuroendocrine;   Non Functioning Neuroendocrine Tumors/NET;   Non Syndromic Neuroendocrine Tumors/NET;   Carcinoids;   Non Functioning
Intervention: Drug: Everolimus
3 Completed Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)
Conditions: Neuroendocrine Tumors;   Metastatic Neuroendocrine Tumors
Intervention: Drug: MK-0646
4 Recruiting Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors
Conditions: Gastrointestinal Tumors;   Pancreatic Tumors;   Gastrointestinal Neuroendocrine Tumors;   Pancreatic Neuroendocrine Tumors
Intervention: Drug: Everolimus
5 Active, not recruiting Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
Conditions: Neuroendocrine Tumor;   Carcinoid Tumor;   Pancreatic Neuroendocrine Tumor
Interventions: Drug: Sorafenib;   Drug: RAD001
6 Active, not recruiting AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
Conditions: Neuroendocrine Tumor;   Carcinoid Tumor;   Pancreatic Neuroendocrine Tumor
Intervention: Drug: AMG 479
7 Active, not recruiting Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
Conditions: Neuroendocrine Tumor;   Carcinoid Tumor;   Pancreatic Neuroendocrine Tumor
Interventions: Drug: SOM230;   Drug: RAD001
8 Completed Pemetrexed in Patients With Advanced Neuroendocrine Tumors
Condition: Neuroendocrine Tumors
Intervention: Drug: Pemetrexed
9 Completed Bevacizumab in Combination With Temozolomide in Patients With Neuroendocrine Tumors
Condition: Neuroendocrine Tumors
Interventions: Drug: Bevacizumab;   Drug: Temozolomide
10 Recruiting A Multicenter Study Evaluating Efficacy and Safety of 177Lu-DOTA-TATE Based on Kidney-Dosimetry in Patients With Disseminated Neuroendocrine Tumors
Conditions: Neuroendocrine Tumors;   Liver Metastases
Intervention: Drug: 177Lu-DOTA-TATE
11 Unknown † Best Therapy for Patients With Neuroendocrine Tumors
Condition: Neuroendocrine Tumors
Intervention:
12 Completed 89Zr-bevacizumab PET Imaging in Patients With Neuroendocrine Tumors
Condition: Neuroendocrine Tumors
Interventions: Drug: 89Zr-bevacizumab;   Drug: Everolimus
13 Completed Lithium for Low-Grade Neuroendocrine Tumors
Condition: Neuroendocrine Tumors
Intervention: Drug: Lithium Carbonate
14 Enrolling by invitation Combination Targeted Radiotherapy in Neuroendocrine Tumors
Condition: Neuroendocrine Tumors
Interventions: Other: 131-I MIBG and 111-In pentetreotide;   Other: 131-I MIBG and In-111 DOTATATE
15 Completed High Dose I-131 Metaiodobenzylguanidine(MIBG) for Metastatic Neuroendocrine Tumors
Conditions: Neuroendocrine Tumors;   Metastases, Neoplasm
Intervention: Drug: I-131 Metaiodobenzylguanidine
16 Unknown † ProGRP, CgA, NSE and TUM2-PK in in Patients With Neuroendocrine Tumors
Condition: Neuroendocrine Tumors
Intervention:
17 Recruiting Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs)
Condition: Neuroendocrine Tumors
Intervention: Drug: Pasireotide LAR
18 Active, not recruiting
Has Results 		Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors
Condition: Pancreatic Neuroendocrine Tumors
Intervention: Drug: Sunitinib
19 Active, not recruiting
Has Results 		Study to Investigate the Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut
Condition: Neuroendocrine Tumors
Interventions: Drug: Octreotide LAR (Long-acting release);   Drug: Placebo
20 Recruiting Neo-adjuvant Peptide Receptor Mediated Radiotherapy With 177Lutetium in Front of Curative Intended Liver Transplantation in Patients With Hepatic Metastasis of Neuroendocrine Tumors (NEO-LEBE)
Conditions: Liver;   Metastasis;   Neuroendocrine Tumors
Interventions: Radiation: 177Lutetium;   Procedure: Liver transplantation
To Top

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
† Indicates status has not been verified in more than two years